The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX®BMI and FRAX®BMD assessment tools to determine patients for intervention

Endokrynologia Polska

Volumn 62, Issue 4, 2011, Pages 290-298

  Badurski, Janusz ^a   Jeziernicka, Elzbieta ^a   Dobreńko, Andrzej ^a   Nowak, Nonna ^a   Daniluk, Stefan ^a   Rybaczuk, Mikołaj ^a   Wiśniowiecka, Magdalena ^a  

^a Polish Foundation of Osteoporosis Research Team   (Poland)

Author keywords

Fracture epidemiology; Osteoporosis; Therapeutic thresholds

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; BODY MASS; BONE DENSITOMETRY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; POPULATION RISK; PRACTICE GUIDELINE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SMOKING; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; COHORT STUDIES; FEMALE; HIP FRACTURES; HUMANS; MASS SCREENING; MIDDLE AGED; OSTEOPOROTIC FRACTURES; POLAND; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 80052578540     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report 843. Geneva 1994.
2. Burger H., De Laet C.E., Van Daele P.L. et al. Risk factors for increased bone loss in an elderly population: The Rotterdam Osteoporosis Study. Am J Epidemiol 2000; 147: 871-879.
3. Wainwright S.A., Phipps K.R., Stone J.V. et al. A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score ≥-2.5. J Bone Miner Res 2001; 16: S155.
4. Nowak N.A., Badurski J.E., Supronik J. et al. Epidemiologia osteoporozy u kobiet w aglomeracji Białegostoku (BOS), I: Gȩstoś? kości a złamania. Postȩpy Osteoartrologii 2003; 14: 1-5.
5. Badurski J.E., Nowak N., Supronik J. et al. Epidemiologia osteoporozy u kobiet w aglomeracji Białegostoku (BOS). II: Analiza czynnikow ryzyka złamań. Postȩpy Osteoartrologii 2003; 2/14: 33-40.
6. Kanis JA on behalf of the Word Heath Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK 2007, and at: www.who.int/chp/topics/reumatic/en/index.html.
7. Kanis J.A., Burlet N., Cooper C. et al on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19/4: 399-428.
8. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Special Position Paper Osteoporos Int 2008; 19: 385-399, and at FRAX-WHO Fracture Risk Assessment Tool: http://www.shef.ac.uk/FRAX/.
9. Badurski J.E., Dobreńko A., Nowak N.A., Jeziernicka E., Daniluk S. Bialystok Osteoporosis Study 2: one intervention threshold for all or an age-dependent one? A simultaneous analysis. Osteoporos Int 2007; 18 (suppl 1).
10. Badurski J.E., Marcinowska-Suchowierska E., Czerwiński E. Wskazania do leczenia osob z wysokim ryzykiem złamania kości - logika stanowiska Światowej Organizacji Zdrowia wobec osteoporozy. Reumatologia 2008; 45 (suppl 3).
11. Czerwiński E., Badurski J., Lorenc R., Osieleniec J. Wytyczne w sprawie diagnostyki osteoporozy i oceny ryzyka złamania w Polsce III Środkowoeuropejskiego Kongresu Osteoporozy i Osteoartrozy, XV Zjazdu Polskiego Towarzystwa Osteoartrologii i Polskiej Fundacji Osteoporozy. Medycyna po Dyplomie 2010; 1: 2-6.
12. Johnell O. When is intervention worthwhile in osteoporosis? Fifth Baltic Bone & Cartilage Conference in Naantali, Finland 2005.
13. Tosteson A.N.A., Melton L.J., Dawson-Hughes B. et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008; 19: 437-448.
14. Dawson-Hughes B, Tosteson, Melton III LJ et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19: 449-458.
15. Fujiwara S., Nakamura T., Orimo H. et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAXR). Osteoporos Int 2008; 19: 429-436.
16. Johansson H., Kanis J.A., McCloskey E.V. et al. A FRAXR model for the assessment of fracture probability in Belgium. Osteoporos Int 2010; 21.
17. Borgstrom F., Strom O., Coelho J. et al. The cost effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 2010; 21: 495-550.
18. Dawson-Hughes B., Looker A.C., Tosteson A.N., Johansson H., Kanis J.A., Melton L.J. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010; 21: 41-52.
19. Skowrońska-Joźwiak E., Wojcicka A., Lorenc R.S., Lewiński A. Comparison of selected methods for fracture risk assessment in postmenopausal women: Analysis of the Łodź population in the EPOLOS study. Pol Arch Med Wewn 2010; 120: 197-202.
20. EMEA European Medicines Agency, London, 16 Nov 2006. Doc.Ref. CPMP/EWP/552/95, Rev.2: Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis.